Design TherapeuticsDSGN +6.68%33 OCF Yield % is -5.52 as of Jul. 06, 2026. GuruFocus rates DSGN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Design Therapeutics ranks better than 57.09% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Design Therapeutics OCF Yield % Related Terms
Design Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Design Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Design Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Design Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Design Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Design Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Design Therapeutics (DSGN) has a OCF Yield % of -5.52 as of Jul. 06, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Design Therapeutics and its competitors. According to the industry distribution chart, Design Therapeutics ranks #605 out of 1410 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Design Therapeutics' OCF Yield % too high?
Design Therapeutics' current OCF Yield % is -5.52. Based on the distribution chart, Design Therapeutics ranks #605 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Design Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Design Therapeutics' OCF Yield % compare to SPRY and GERN?
According to the Biotechnology industry distribution chart, Design Therapeutics ranks #605 out of 1410 companies for OCF Yield %. This puts Design Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Design Therapeutics and its competitors. Design Therapeutics's current OCF Yield % is -5.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Design Therapeutics stock overvalued right now?
Design Therapeutics (DSGN) has a current OCF Yield % of -5.52. The current OCF Yield % is -5.52. Design Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Design Therapeutics (DSGN), the current OCF Yield % is -5.52 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
33GF Score
Get the complete analysis for DSGN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSGN has been successfully added to your 
